Pentoxifylline Increases Retinal Capillary Blood Flow Velocity in Patients with Diabetes

Archives of Ophthalmology

Volumn 111, Issue 12, 1993, Pages 1647-1652

  Sonkin, Peter L ^a,c   Kelly, Larry W ^a   Sinclair, Stephen H ^b   Hatchell, Diane L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PLACEBO;

ADULT; ARTICLE; BLOOD VISCOSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFECT; FIBRINOGEN SYNTHESIS; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; MICROVASCULATURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINA BLOOD FLOW; RETINA CAPILLARY;

ADMINISTRATION, ORAL; BLOOD FLOW VELOCITY; BLOOD VISCOSITY; CAPILLARIES; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FIBRINOGEN; HEMORHEOLOGY; HUMAN; MALE; MIDDLE AGE; PENTOXIFYLLINE; REGIONAL BLOOD FLOW; RETINAL VESSELS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027527489     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.1993.01090120069024     Document Type: Article

References (43)

1. DeVaro J, Chumdermpodetsuk R, Edelman R, Sinclair S, MacGregor R.R. Polymorphonuclear (PMN) filterability in diabetes mellitus. Invest Ophthalmol Vis Sci. 1988;29:181.
2. Ernst E, Matrai A. Altered red and white blood cell rheology in type II diabetes. Diabetes. 1986;35:1412–1415.
3. Freedman SF, Hatchell DL. Enhanced superoxide radical production by stimulated polymorphonuclear leukocytes in a cat model of diabetes. Exp Eye Res. 1992;55:767–773.
4. Schröder S, Palinski W, Schmid-Schönbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81–100.
5. Sonkin PL, Freedman SF, Needham D, Rao KMK, Hatchell DL. Pentoxifylline modulates deformability, F-actin content, and superoxide anion production of polymorphonuclear leukocytes from diabetic cats. Exp Eye Res. 1992;55:831–838.
6. Sonkin PL, Sinclair SH, Hatchell DL. Pentoxifylline improves retinal capillary blood flow velocity and whole blood viscosity. Am J Ophthalmol. 1993;115:775–780.
7. Kelly LW, Barden CA, Tiedeman JS, Hatchell DL. Alterations in viscosity and filterability of whole blood and blood cell subpopulations in diabetic cats. Exp Eye Res. 1993;56:341–347.
8. Millar HR, Simpson JG, Stalker AL. An evaluation of the heat precipitation method for plasma fibrinogen estimation. J Clin Pathol. 1971;24:827–830.
9. Riva CE, Petrig B. Blue field entoptic phenomenon and blood velocity in the retinal capillaries. J Opt Soc Am. 1980;70:1234–1238.
10. Sinclair SH, Azar-Cavanagh M, Soper KA, Tuma RF, Mayrovitz HN. Investigation of the source of the blue field entoptic phenomenon. Invest Ophthalmol Vis Sci. 1989;30:668–673.
11. Schmid-Schönbein GW, Skalak R, Usami S, Chien S. Cell distribution in capillary networks. Microvasc Res. 1980;19:18–44.
12. Mayrovitz HN. The relationship between leukocyte and erythrocyte velocity in arterioles. In: Bagge U, Born GVR, Gaehtgens P, eds. White Blood Cells, Morphology, and Rheology Related to Function. The Hague, the Netherlands: Nijhoff; 1982:82–88.
13. Mayrovitz HN. Rubin R. Leukocyte distribution to arteriolar branches: dependence on microvascular blood flow. Microvasc Res. 1985;9:282–294.
14. Sinclair SH. Macular retinal capillary hemodynamics in diabetic patients. Ophthalmology. 1991;98:1580–1586.
15. Robinson F, Chen S, Petrig BL, Grunwald JE, Riva CE. The acute effect of topical epinephrine on macular blood flow in humans. Invest Ophthalmol Vis Sci. 1992;33:18–22.
16. Robinson F, Petrig BL, Sinclair SH, Riva CE, Grunwald JE. Does topical phenylephrine, tropicamide, or proparacaine affect macular blood flow? Ophthalmology. 1985;92:1130–1132.
17. Lotfi K, Grunwald JE, Furubavashi C. The effect of caffeine on the human macular circulation. Invest Ophthalmol Vis Sci. 1990;31:567.
18. Nash GB, Thomas PRS, Dormandy JA. Abnormal flow properties of white blood cells in patients with severe ischaemia of the leg. BMJ. 1988;296:1699–1701.
19. Vermes I, Steinmetz ET, Zeyen LJJM, van der Veen EA. Rheological properties of white blood cells are changed in diabetic patients with microvascular complications. Diabetologia. 1987;30:434–436.
20. Wierusz-Wysocka B, Wysocki H, Siekierta H, Wykretowiez A, Szczepanik A, Klimas R. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol. 1987;42:519–523.
21. Andersen B, Goldsmith GH, Spagnuolo P. Neutrophil adhesive dysfunction in diabetes mellitus: the role of cellular and plasma factors. J Lab Clin Med. 1988;111:275–285.
22. Kohner EH. Retinal ischemia. In: Ryan SJ, Schacat AP, Murphy RP, Patz A, eds. Retina. St Louis, Mo: Mosby-Year Book; 1989;2:89–97.
23. Ehrly AM. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease. Angiology. 1976;27:188–196.
24. Schubotz R, Mühlfellner O. The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane. Curr Med Res Opin. 1977;4:609–617.
25. Angelkort B, Maurin N, Boateng K. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Curr Med Res Opin. 1979;6:255–258.
26. Gaillard S, Schooneman F, Voisin P, et al. Effects compares sur la filtrabilite in vivo chez l'homme de deux formes galeniques de la pentoxifylline. Ann Med Nancy. 1979;18:1099–1102.
27. Manrique RV, Manrique V. Platelet resistance to prostacyclin: enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline. Angiology. 1987;38:101–108.
28. Sonkin PL, Chen LE, Seaber AV, Hatchell DL. Vasodilator action of pentoxifylline on microcirculation of rat cremaster muscle. Angiology. 1992;43:462–469.
29. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol. 1989;257(Heart Circ Physiol 26):H33-H37.
30. Cogan DG, Merola L, Laibson PR. Blood viscosity, serum hexosamine and diabetic retinopathy. Diabetes. 1961;10:393–395.
31. Hoare EM, Barnes AJ, Dormandy JA. Abnormal blood viscosity in diabetes mellitus and retinopathy. Biorheology. 1976;13:21–25.
32. Rao KMK, Simel DL, Cohen HJ, Crawford J, Currie MS. Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. J Lab Clin Med. 1990;115:738–744.
33. Rössner M, Müller R. On the assessment of the efficacy of pentoxifylline (Trental). J Med. 1987;18:1–15.
34. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4:297–307.
35. Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica. 1976;1:172–179.
36. Ehrly AM. Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. IRCS J Med Sci. 1982;19:401–402.
37. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104:66–72.
38. Insel J, Halle AA, Mirvis DM. Efficacy of pentoxifylline in patients with stable angina pectoris. Angiology. 1988;39:514–519.
39. Hartmann A, Tsuda Y. A controlled study on the efficacy of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease. Angiology. 1988;39:449–457.
40. Schultheiss R, Leuwer R, Leniger-Follert E, Wassmann H, Wüllenweber R. Tissue p02 of human brain cortex: method, basic results and effects of pentoxifylline. Angiology. 1987;38:221–225.
41. Herskovits E, Famulari A, Tamaroff L, et al. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol. 1985;24:73–81.
42. Wolfe KA, Sebag J, Sadun AA, Brown S, Tang M, Charles MA. Effects of pentoxifylline on ocular blood flow in non-proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1991;32:863.
43. Ferrari E, Fioravanti M, Patti AL, Viola C, Solerte SB. Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients. Pharmatherapeutica. 1987;5:26–39.